Related Experiment Videos
Biologic activity of MCNU: a new antitumor agent
Cancer Treatment Reports
|June 1, 1979
Summary
A novel nitrosourea derivative, methyl-6-[[[(2-chloroethyl)nitrosoamino]carbonyl]-amino]-6-deoxy-alpha-D-glucopyranoside (MCNU), shows significant anti-cancer effects against various mouse tumors. MCNU demonstrates effectiveness with lower bone marrow toxicity compared to some existing treatments.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Nitrosourea derivatives are a class of chemotherapeutic agents.
- Development of novel compounds with improved efficacy and reduced toxicity is crucial in cancer treatment.
Purpose of the Study:
- To synthesize and evaluate a novel nitrosourea derivative, MCNU.
- To assess the anti-cancer activity and toxicity profile of MCNU.
Main Methods:
- Synthesis of methyl-6-[[[(2-chloroethyl)nitrosoamino]carbonyl]-amino]-6-deoxy-alpha-D-glucopyranoside (MCNU).
- Evaluation of MCNU's life-prolongation and growth-inhibitory effects in mouse tumor models (L1210 leukemia, adenocarcinoma 755, etc.).
- Comparison of MCNU's efficacy and toxicity with existing agents like chlorozotocin and CCNU via different administration routes.
Main Results:
- MCNU demonstrated significant life-prolongation and growth-inhibitory effects against multiple mouse tumors.
- MCNU was effective against L1210 leukemia via ip, oral, or iv administration, with a superior therapeutic ratio compared to chlorozotocin or CCNU when administered ip.
- MCNU showed comparable efficacy to methyl-CCNU against established Lewis lung carcinoma, with less bone marrow toxicity than CCNU but more than chlorozotocin.
Conclusions:
- MCNU is a promising novel nitrosourea derivative with broad-spectrum anti-cancer activity.
- MCNU offers a potentially improved therapeutic index compared to certain existing nitrosoureas.
- Further investigation into MCNU's clinical potential is warranted.